Regeneus anticipates entering a binding arrangement with a manufacturing and commercialisation partner for its Progenza mesenchymal stem cell therapy technology in Japan by the end of the current quarter. Following on from the positive safety review of its STEP Phase I trial of Progenza in patients with knee osteoarthritis, it has already begun procuring donor material in preparation for manufacturing Progenza for a Phase II trial in Japan. Our valuation is virtually unchanged at A$108m (A$0.
14 Sep 2016
Japan licence deal close to finalisation
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Japan licence deal close to finalisation
Cambium Bio Ltd (CMB:ASX) | 0 0 -7.7% | Mkt Cap: 25.1m
- Published:
14 Sep 2016 -
Author:
Dr Dennis Hulme -
Pages:
7
Regeneus anticipates entering a binding arrangement with a manufacturing and commercialisation partner for its Progenza mesenchymal stem cell therapy technology in Japan by the end of the current quarter. Following on from the positive safety review of its STEP Phase I trial of Progenza in patients with knee osteoarthritis, it has already begun procuring donor material in preparation for manufacturing Progenza for a Phase II trial in Japan. Our valuation is virtually unchanged at A$108m (A$0.